Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Thousands of Massachusetts biotech employees face job losses amid industry turmoil. Laid-off workers share their struggles ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates moving forward.

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Vertex Pharmaceuticals' stock took a hard hit, dropping 20% due to setbacks with VX-993 and suzetrigine, wiping out $91 ...

Boston's new commuter ferry connects Seaport District and North Station, funded by the city and private sector.

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program ...